HRP20231035T1 - Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe - Google Patents

Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe Download PDF

Info

Publication number
HRP20231035T1
HRP20231035T1 HRP20231035TT HRP20231035T HRP20231035T1 HR P20231035 T1 HRP20231035 T1 HR P20231035T1 HR P20231035T T HRP20231035T T HR P20231035TT HR P20231035 T HRP20231035 T HR P20231035T HR P20231035 T1 HRP20231035 T1 HR P20231035T1
Authority
HR
Croatia
Prior art keywords
conjugated
monoclonal antibody
antigen
bed bugs
binding fragment
Prior art date
Application number
HRP20231035TT
Other languages
English (en)
Inventor
William John Hall
Min Wang
Original Assignee
Redcoat Solutions, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redcoat Solutions, Inc. filed Critical Redcoat Solutions, Inc.
Publication of HRP20231035T1 publication Critical patent/HRP20231035T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B22F1/0545—Dispersions or suspensions of nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004—Preparation of sols
    • B01J13/0043—Preparation of sols containing elemental metal
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2301/00—Metallic composition of the powder or its coating
    • B22F2301/25—Noble metals, i.e. Ag Au, Ir, Os, Pd, Pt, Rh, Ru
    • B22F2301/255—Silver or gold
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2304/00—Physical aspects of the powder
    • B22F2304/05—Submicron size particles
    • B22F2304/054—Particle size between 1 and 100 nm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2304/00—Physical aspects of the powder
    • B22F2304/05—Submicron size particles
    • B22F2304/056—Particle size above 100 nm up to 300 nm
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (16)

1. Monoklonska antitijela protiv krevetnih stjenica proizvedena pomoću: (a) hibrida deponiranog u Američkoj zbirci tipova kultura (American Type Culture Collection – ATCC) pod pristupnim brojem PTA-122644 (BB2), ili njegovog fragmenta vezanja antigena ili (b) hibrida deponiranog u Američkoj zbirci tipova kultura – ATCC pristupnim brojem PTA-122645 (BB7) ili njegovog fragmenta vezanja antigena.
2. Konjugirano monoklonsko antitijelo ili konjugirani fragment vezanja antigena koji obuhvaća monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antigena sukladno patentnom zahtjevu 1 i sredstvo otkrivanja.
3. Konjugirano monoklonsko antitijelo ili konjugirani fragment vezanja antigena sukladno patentnom zahtjevu 2, pri čemu je sredstvo za detekciju enzimska oznaka, radio-oznaka, fluorofor, kromofor, sredstvo koji se koristi prilikom medicinskih snimanja, metal, metalni ion, koloidno zlato ili nanočestice zlata.
4. Konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno patentnim zahtjevima 2 ili 3, koje obuhvaća monoklonsko antitijelo protiv krevetnih stjenica proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura ATCC pod pristupnim brojem PTA-122644 (BB2) ili njegovog fragmenta vezanja antigena.
5. Konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno patentnim zahtjevima 2 ili 3, obuhvaća monoklonsko antitijelo protiv krevetnih stjenica proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura ATCC pod pristupnim brojem PTA-122645 (BB7) ili njegovog fragmenta vezanja antigena.
6. Pripravak koja obuhvaća monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antigena sukladno patentnom zahtjevu 1 konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno bilo kojem patentnom zahtjevu od 2 do 5 ili kombinaciju navedenih.
7. Pripravak sukladno patentnom zahtjevu 6 nadalje obuhvaća: (a)(1) monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura ATCC pod pristupnim brojem PTA-122644 (BB2), i (2) monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura (ATCC) pod pristupnim brojem PTA-122645 (BB7) ili konjugirano antitijelo sukladno patentnom zahtjevu 5; ili (b)(1) monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura ATCC pod pristupnim brojem PTA-122645 (BB7), i (2) konjugirano antitijelo sukladno patentnom zahtjevu 4.
8. Pribor koji obuhvaća monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antitijela sukladno patentnom zahtjevu 1, konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno bilo kojem od patentnih zahtjeva 2 do 5, pripravak sukladno patentnim zahtjevima 6 ili 7 ili kombinaciju navedenih.
9. Hibrid koji je sposoban za proizvodnju monoklonskog antitijela protiv krevetnih stjenica, pri čemu je hibrid deponiran u Američkoj zbirci tipova kultura (ATCC) pod pristupnim brojem PTA-122644 (BB2) ili pristupnim brojem PTA-122645 (BB7).
10. Izolirana stanica koja proizvodi monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antitijela sukladno patentnom zahtjevu 1.
11. Postupak proizvodnje monoklonskog antitijela protiv krevetnih stjenica ili fragment vezanja antigena sukladno patentnom zahtjevu 1, koje obuhvaća (a) kultiviranje stanice sukladno patentnom zahtjevu 10 i (b) izoliranje monoklonskog antitijela protiv krevetnih stjenica ili fragment vezanja antigena iz kultivirane stanice.
12. Postupak otkrivanja krevetnih stjenica koji obuhvaća dovođenje u kontakt uzorka koji obuhvaća antigen krevetne stjenice s monoklonskim antitijelom protiv krevetnih stjenica ili fragment vezanja antigena sukladno patentnom zahtjevu 1, konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno bilo kojem od patentnih zahtjeva 2 do 5, pripravak sukladno patentnim zahtjevima 6 ili 7 ili kombinaciju navedenih i otkrivanje vezanja antigena krevetnih stjenica na monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antigena, konjugiranog antitijela ili konjugiranog fragmenta vezanja antigena, pripravka ili njihove kombinacije, pri čemu otkrivanje poželjno obuhvaća izvođenje analize bočnog protoka.
13. Postupak sukladno patentnom zahtjevu 12, pri čemu je taj uzorak doveden u kontakt s monoklonskim antitijelom protiv krevetnih stjenica sukladno patentnom zahtjevu 1 i konjugiranim antitijelom sukladno bilo kojem od patentnih zahtjeva 2 do 5.
14. Postupak sukladno patentnom zahtjevu 13, pri čemu: (a) monoklonsko antitijelo je protiv krevetnih stjenica je monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura (ATCC) pod pristupim brojem PTA-122644 (BB2) i konjugirano antitijelo je konjugirano antitijelo sukladno patentnom zahtjevu 5 ili (b) monoklonsko antitijelo je protiv krevetnih stjenica monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura (ATCC) pod pristupnim brojem PTA-122645 (BB7) i konjugirano antitijelo je konjugirano antitijelo sukladno patentnom zahtjevu 4.
15. Postupak sukladno bilo kojem od patentnih zahtjeva 12 do 14, pri čemu taj postupak nadalje obuhvaća prikupljanje uzorka koji obuhvaća antigen krevetnih stjenica s uređajem za prikupljanje i izlučivanje antigena iz tog uzorka.
16. Postupak sukladno patentnom zahtjevu 15, pri čemu je uređaj za prikupljanje bris.
HRP20231035TT 2015-10-21 2016-10-21 Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe HRP20231035T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562244189P 2015-10-21 2015-10-21
EP16858386.2A EP3365367B1 (en) 2015-10-21 2016-10-21 Anti-bed bug monoclonal antibodies and methods of making and uses thereof
PCT/US2016/058300 WO2017070603A1 (en) 2015-10-21 2016-10-21 Anti-bed bug monoclonal antibodies and methods of making and uses thereof

Publications (1)

Publication Number Publication Date
HRP20231035T1 true HRP20231035T1 (hr) 2023-12-22

Family

ID=58558142

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231035TT HRP20231035T1 (hr) 2015-10-21 2016-10-21 Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe

Country Status (13)

Country Link
US (1) US10768172B2 (hr)
EP (2) EP3365367B1 (hr)
AU (2) AU2016342373B2 (hr)
CA (1) CA3041460A1 (hr)
ES (1) ES2953484T3 (hr)
HR (1) HRP20231035T1 (hr)
HU (1) HUE063822T2 (hr)
MA (1) MA45831B1 (hr)
MD (1) MD3365367T2 (hr)
MX (2) MX2018004986A (hr)
PL (1) PL3365367T3 (hr)
RS (1) RS64530B1 (hr)
WO (1) WO2017070603A1 (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3370515T3 (da) 2015-10-21 2022-05-02 Redcoat Solutions Inc Anordning til påvisning af væggelus
CN114747552B (zh) 2017-05-22 2023-12-29 科迪华农业科技有限责任公司 臭虫的选择性检测
JP2022510827A (ja) 2018-11-21 2022-01-28 コルテバ アグリサイエンス エルエルシー ナンキンムシの選択的検出

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
EP1086375A4 (en) 1998-06-12 2004-12-15 New Horizons Diagnostics Inc COLLOIDAL COLORIMETRIC TESTS IN CONTINUOUS FLOW AND SIDE FLOW USING SOLUBLE SUBMICRONIC PARTICLES
BR0014734A (pt) * 1999-10-12 2002-06-18 Connex Ges Zur Optimierung Von Método melhorado para detectar microorganismos resistentes a ácido na evacuação
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7214542B2 (en) 2003-01-30 2007-05-08 Michael Hutchinson Method of processing assay test results
US7220597B2 (en) 2003-01-30 2007-05-22 Zin Benedict L Assay test device and method of making same
WO2004084841A2 (en) * 2003-03-27 2004-10-07 Heska Corporation Novel anti-feline albumin antibodies and methods of detecting early renal disease
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
EP2357476A3 (en) 2005-07-27 2012-03-21 Cytosignet, Inc. Detection and measurement of blood-feeding activity
US7591099B2 (en) 2005-08-30 2009-09-22 Ecolab Inc. Bed bug monitor
JP5066575B2 (ja) 2006-10-23 2012-11-07 ダウ アグロサイエンシィズ エルエルシー ナンキンムシ検出、監視及び防除技術
AU2013200548B2 (en) 2006-10-23 2015-06-18 Ecolab Usa Inc. Bedbug detection, monitoring and control techniques
WO2008073895A2 (en) 2006-12-08 2008-06-19 Binax, Inc. Methods and devices for testing saliva
EP1933145B1 (en) 2006-12-11 2011-09-28 AraGen Biotechnology Co. Ltd. Rapid immunochromatographic detection by amplification of the colloidal gold signal
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
AU2008224950B2 (en) 2007-03-13 2013-10-03 National Jewish Medical And Research Center Methods for generation of antibodies
US8435461B2 (en) 2007-04-20 2013-05-07 Quidel Corporation Analytical devices with integrated desiccant
US20090155921A1 (en) 2007-12-12 2009-06-18 Arbor Vita Corporation Method and apparatus for reading test strips
EP2287174B8 (en) 2008-01-18 2016-12-07 Bio-Rad Laboratories, Inc. Enhanced purification of antibody fragments by apatite chromatography
GB0809995D0 (en) 2008-05-31 2008-07-09 Spd Swiss Prec Diagnostics Gmb Assay device
GB0900669D0 (en) 2009-01-16 2009-02-25 Bed Bugs Ltd Pest control
US20100212213A1 (en) 2009-02-25 2010-08-26 Hope Iii Joe Harold Detection device and method for monitoring bed bug infestation
JP2012520315A (ja) 2009-03-13 2012-09-06 エフ エム シー コーポレーション トコジラミを誘引するための組成物
US8577986B2 (en) 2010-04-02 2013-11-05 Microsoft Corporation Mapping RDMA semantics to high speed storage
US20110289824A1 (en) 2010-05-28 2011-12-01 Tai-Teh Wu Compounds, methods, and devices for detecting and/or treating insect infestation
FI20115285A0 (fi) 2011-03-24 2011-03-24 Reagena Ltd Oy Menetelmä pikatestin suorittamiseksi
US9458512B2 (en) 2011-07-05 2016-10-04 Ernest Colaizzi Kit for the detection of bed bugs
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9140693B2 (en) 2011-12-23 2015-09-22 Abbott Point Of Care Inc. Integrated test device for optical detection of microarrays
US9188583B2 (en) 2012-02-29 2015-11-17 Sri International Ectoparasite detection
US20130208114A1 (en) 2013-01-25 2013-08-15 Jody Arthur Balsam Digital Bedbug Indicator: A bedbug insect peripheral electronic detection unit device
GB2524307B (en) 2014-03-20 2016-04-20 Rentokil Initial Plc Apparatus
JP2017511494A (ja) 2014-04-17 2017-04-20 ゼット−インターグレイテッド ディジタル テクノロジーズ，インク．Ｚ−Ｉｎｔｅｇｒａｔｅｄ Ｄｉｇｉｔａｌ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． 電子試験装置によるデータ通信
JP2018533619A (ja) 2015-08-31 2018-11-15 エアミッド ヘルス グループ リミテッド 新規タンパク質および検出法
DK3370515T3 (da) * 2015-10-21 2022-05-02 Redcoat Solutions Inc Anordning til påvisning af væggelus

Also Published As

Publication number Publication date
CA3041460A1 (en) 2017-04-27
EP4273235A2 (en) 2023-11-08
MD3365367T2 (ro) 2024-02-29
WO2017070603A1 (en) 2017-04-27
MA45831A (fr) 2019-06-12
AU2016342373A1 (en) 2018-06-07
AU2023282327A1 (en) 2024-01-18
EP3365367A1 (en) 2018-08-29
PL3365367T3 (pl) 2023-10-30
AU2016342373B2 (en) 2023-09-21
HUE063822T2 (hu) 2024-02-28
MX2018004986A (es) 2019-01-14
ES2953484T3 (es) 2023-11-13
EP3365367A4 (en) 2019-06-12
EP3365367B1 (en) 2023-06-07
MX2023009584A (es) 2023-08-23
RS64530B1 (sr) 2023-09-29
EP4273235A3 (en) 2024-01-17
EP3365367C0 (en) 2023-06-07
US10768172B2 (en) 2020-09-08
WO2017070603A9 (en) 2018-05-17
US20170137501A1 (en) 2017-05-18
MA45831B1 (fr) 2023-10-31
US20200363405A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
HRP20192347T1 (hr) Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora
JP2017518366A5 (hr)
RU2015103228A (ru) Антитела против тау
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
HRP20160461T1 (hr) Solubilna humana st-2 antitijela i eseji
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
RU2014117161A (ru) Композиции и способы испытаний на токсикогенность
EA200971124A1 (ru) Множественный анализ образцов крови
HRP20231035T1 (hr) Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe
AR098126A1 (es) Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos
WO2008027942A3 (en) Combination hepatitis c virus antigen and antibody detection method
US20150111784A1 (en) Detecting Cells Secreting A Protein of Interest
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
RU2013142334A (ru) КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ОПРЕДЕЛЕНИЯ НЕ4а
RU2014146707A (ru) Антитела против тофацитиниба и их применение для лекарственного мониторинга
MX2018008809A (es) Anticuerpos monoclonales especificos para el antigeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por adv.
RU2014140432A (ru) Способ прогнозирования риска развития злокачественного новообразования или диагностики злокачественного новообразования у особи женского пола
CN103880960B (zh) 一种抗cd10分子的单克隆抗体及其应用
EA201692071A1 (ru) Иммуноанализ и антитела для обнаружения хромогранина а
CN103732627B (zh) 包含抗-atic自身免疫抗体的肝癌诊断标记物以及包含其抗原的肝癌诊断用组合物
FR2968767B1 (fr) Procede et coffret pour le diagnostic in vitro du cancer de la prostate
WO2016069762A3 (en) Subject anti-hcv antibody detection assays employing ns3 capture peptides
CN109061166B (zh) 一种用于检测牛结核病的ELISpot检测试剂盒
RU2009124225A (ru) Мышиные моноклональные антитела, связывающиеся с антигеном f1 из yersinia pestis, способ их получения с использованием дрожжей, способ и набор для детекции yersinia pestis